Agios Pharmaceuticals, Inc. (AGIO) — Financial statements
Income statement, balance sheet, and cash flow for Agios Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 54↑48.0% | 36↑36.1% | 27↑88.4% | 14 | 0.00 | |
| Cost of Revenue | 12↑176.6% | 4↓56.2% | 10↑457.7% | 2↓90.9% | 19 | |
| Gross Profit | 43↑31.5% | 32↑86.7% | 17↑38.2% | 13↑166.8% | -19 | |
| Operating Expenses | ||||||
| R&D Expenses | 334↑11.0% | 301↑4.3% | 289↑3.2% | 280↑8.9% | 257 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 180↑15.0% | 157↑30.8% | 120↓1.5% | 122↑0.2% | 121 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -19 | |
| Operating Expenses | 515↑12.3% | 458↑12.1% | 409↑1.8% | 402↑11.7% | 360 | |
| Total Costs & Expenses | 526↑13.8% | 462↑10.5% | 418↑3.7% | 403↑6.6% | 378 | |
| Operating Results | ||||||
| Operating Income | -472↓10.9% | -426↓8.7% | -391↓0.6% | -389↓2.8% | -378 | |
| Depreciation & Amortization | 5↓8.4% | 6↓14.6% | 7↓22.7% | 9↓54.4% | 19 | |
| EBITDA | -467↓11.2% | -420↓9.2% | -385↓1.2% | -380↓12.7% | -338 | |
| EBIT | -472↓10.9% | -426↓8.7% | -391↓0.6% | -389↓9.1% | -357 | |
| Interest & Other Income | ||||||
| Net Interest Income | 56↑17.3% | 48↑44.2% | 33↑160.6% | 13↑1430.3% | 0.84 | |
| Interest Income | 56↑17.3% | 48↑44.2% | 33↑160.6% | 13↑1430.3% | 0.84 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -22 | |
| Other Income / Expenses | 58↓94.9% | 1,144↑2802.9% | 39↓74.9% | 157↑617.8% | 22 | |
| Income Before Tax | -414↓157.6% | 718↑303.9% | -352↓51.9% | -232↑35.0% | -357 | |
| Income Tax Expense | -1↓102.3% | 44 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -413↓161.3% | 674↑291.4% | -352↓51.9% | -232↑35.0% | -357 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 1,961 | |
| Net Income | -413↓161.3% | 674↑291.4% | -352↓51.9% | -232↓114.4% | 1,605 | |
| Bottom-Line Net Income | -413↓161.3% | 674↑291.4% | -352↓51.9% | -232↑39.7% | -384 | |
| EPS (Basic) | -7.12↓160.0% | 11.86↑287.4% | -6.33↓49.6% | -4.23↑33.5% | -6.36 | |
| EPS (Diluted) | -7.12↓161.2% | 11.64↑283.9% | -6.33↓49.6% | -4.23↑33.5% | -6.36 | |
| Weighted Average Shares | 58↑2.1% | 57↑2.1% | 56↑1.6% | 55↓9.4% | 60 | |
| Weighted Average Diluted Shares | 58↑0.1% | 58↑4.0% | 56↑1.6% | 55↓9.4% | 60 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.